Cell Therapeutics Inc. is closer to getting French approval of Pixuvri, the company’s cancer drug.
The French National Health Authority’s Transparence Commission on Monday granted market access to the drug, which was developed to treat adult patients with multiple relapses or refractory aggressive B-cell non-Hodgkin lymphoma.
The next step in the country’s pharmaceutical reimbursement system would be the inclusion of Pixuvri on a list of medicines approved for hospital use. That decision…
Cell Therapeutics Inc. is closer to getting French approval of Pixuvri, the company’s cancer drug.
The French National Health Authority’s Transparence Commission on Monday granted market access to the drug, which was developed to treat adult patients with multiple relapses or refractory aggressive B-cell non-Hodgkin lymphoma.
The next step in the country’s pharmaceutical reimbursement system would be the inclusion of Pixuvri on a list of medicines approved for hospital use. That decision…